Faiena I, et al. - Researchers evaluated the impact of neoadjuvant chemotherapy (NAC) on the survival of the patients with residual urothelial carcinoma (UC) after radical cystectomy. In patients with residual UC, findings suggested the association of NAC with a significant survival benefit in higher stage disease only. Also, there was a less likeliness of residual disease in those treated with NAC or at an academic centre. NAC receiving patients were younger and healthier, treated at an academic centre, and presented with a higher stage. More prudent patient selection for NAC was suggested on account of the toxicity of NAC.